{"name":"Origin Biosciences","slug":"origin-biosciences","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNR0U4dExGdW8wS2ZDZTRKdzk5VXQxa0NhZ1g3cG9NcU42ZVVPb2ZqX2hwWi1BNzlYQlM4SnlQQkJiVUJjMTIyNXpZc0Vub3FDS2l3UEJYaGZiT3NncXktaDllLVl4OHI2Y2ZPckM4bzhrT3lfdWpjZUZZbGdVem9iY0YxbUt5ZTQ3RU5tSndGVTVvNlZUdlN6dTdkc0hVMVdEX2pRTDRacHdJTjd0cTNmX1d3ZmtZdUJtTXNmTWNNa0M5MjBtNzBsMg?oc=5","date":"2026-02-10","type":"pipeline","source":"Pharmaceutical Executive","summary":"Pharma Funding Roundup: QuantX Biosciences, Pandorum Technologies Complete Series B Financing Rounds - Pharmaceutical Executive","headline":"Pharma Funding Roundup: QuantX Biosciences, Pandorum Technologies Complete Series B Financing Rounds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSUt6TjhqalJoV0RyTGFjdVoyaUdFQ3VFbHlVNXBpQ2lPMXdmU2pXbGxSTWtmY0otM0dTZktkS3pXVXk2Y2RYTnAtOUJJTDlzRkFwOXlkaDNMTS1lYm4wMXNZbGpuYWhTUFZHUlF2clJHU2tLaVQ3WXFDQ1E5WFJBR2hiY3dPNUFQbURaZjNJOGlUU3lSTGZHUkxJOGtBaUJnTW9SZ3JtMXN2bUdMY3psLU15dzBMX2ZR?oc=5","date":"2026-01-07","type":"pipeline","source":"McKinsey & Company","summary":"The emerging epicenter: Asia’s role in biopharma’s future - McKinsey & Company","headline":"The emerging epicenter: Asia’s role in biopharma’s future - McKinsey & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOdl93M3h0YXR0MnYzZzRFWTlyOGNiajloUW4zNVZSek8za1c0bXRmb0JiWTYyX3VpOGIwbHVLUGdyemp6T1FVc0trODlhdVVlNlBaMHpFTUZQNkFTbmtFeEVyWXRnOTg3Z20yVkdRTFd1RDc0R2dGcU5CMzhKQmVSSzhvUTZjbHJ1dTdLMmQ4cldJR09jMlp4SHB4UQ?oc=5","date":"2025-12-22","type":"deal","source":"Fierce Biotech","summary":"Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech","headline":"Gilead pays $35M to license pair of HSV assets from Assembly Bio pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQOEdtTV9FSTJpbko0VDFFUXhsazZtanVxTDQwenNTLWtnR1JOT2pWZHZPcDA0bFBCMzB4M1I5eVlXbFdpekxDZGFxWHhXa2tSUHhuYmFrUk9wRVBtSkdfYmxjLUtkSFNlUWozeDRncjhDMDl5RWtlV2J4ZDVBdUhfSWxzQVNPWXIxM1pObHAzWGRuNnlIUF9vRnJMd0hqYWc?oc=5","date":"2025-09-17","type":"pipeline","source":"BioPharma Dive","summary":"Ollin debuts with $100M and plans to challenge top-selling eye drugs - BioPharma Dive","headline":"Ollin debuts with $100M and plans to challenge top-selling eye drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNUUpOeDA4YXBKMjlrWVQ1LXdEQ1QzakVjMDd1VktoSlI1M05LUHZpdDY5SGRWUkVfX0pHZTRDTkRjTlkyc3lkT0ttQUhLNmdSdzFyTzFKYTlRN1dwSDg4WklWQ0hvQ19GLTMwUFp2R1c4Q0dqbUNTSjItSmFzaVpsc2FwazQzSkhwWU1wUFNGMXhzR3c?oc=5","date":"2025-07-23","type":"pipeline","source":"Pharma Voice","summary":"Who is Dr. George Tidmarsh, the new director of CDER? - Pharma Voice","headline":"Who is Dr. George Tidmarsh, the new director of CDER?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNWGxIQThZakc3VWloSkRXVzlQR3ZWRUpBeHFGNXZCTGRJaEZxMDJzVHRUUDF5dW9rWFVFQnhzUmdZRXYycXMwTWRrNi04Nl9qTlp0NzZqMTRVMldVbjJVUHQwTXlFMGFVNTRuS2NKS0tyR2MzZDBScWVJZTdNNlJwWmNJOGtjd01LRm9KMmxTSDdlZkt5bXJVblB6ZURZVDdCTmNsd096cmxyaE5FV2JVU0EzSUZmb1dFZ2JlSW5YTHZKTFV6bWtwbA?oc=5","date":"2025-06-18","type":"pipeline","source":"Deloitte","summary":"Measuring the return from pharmaceutical innovation 2024 - Deloitte","headline":"Measuring the return from pharmaceutical innovation 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5SeXFxX3JWbW53bmM2QWw2MldoQUhEZzgtdmpWdlAya1dUMGtjSUFIOG1VYzQ4aDNwMWZDaHlvSkRSdzJYUWk3R1VETHZWWFI1clp6bXkzSTFPQVVYY0lUNFBNcWxLeHN2SUQ1WGZscGY5bWJvQWhJ?oc=5","date":"2021-06-25","type":"regulatory","source":"Anton Health","summary":"FDA Approves Nulibry for Ultra Rare Disease | Anton Rx Report - Anton Health","headline":"FDA Approves Nulibry for Ultra Rare Disease | Anton Rx Report","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5ORTEzN2JCdlFTc3NBWmpVU08tazBXUHdyaGt3b05yTE9FUXRuajhTbEU0V3BqcUxXLURpT1Aza3cwRmU1cEZTZ205WkJ2QlI0anFRcmJZc1NGQ3ptNW85bTJyamJmZXZ2RW90bERneFBySjdudFE?oc=5","date":"2021-05-06","type":"trial","source":"Clinical Trials Arena","summary":"Nulibry™ (Fosdenopterin) for the Treatment of Molybdenum Cofactor Deficiency Type A - Clinical Trials Arena","headline":"Nulibry™ (Fosdenopterin) for the Treatment of Molybdenum Cofactor Deficiency Type A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNcUVya09nODdYTjlJUlhJbXhUcFE4ZW9oQWpBUVRNR2NSZDBfTnF5c3N0YUxacldLWFpIakhyYzZScWxtcERsb1FKVVNoVy1nYnZtOWVPWmUyYjhPQ1RvejlnVjhOaHJOSEtXNjc5bmstNTNXUlRzWXdTTFlFMzRSOGxzVHNZZWlZa1hoMVByOFpZNzc2VEpXYTZYQlJ5aDYtM09ncWVUTEltTHRvY0tZ?oc=5","date":"2021-03-01","type":"regulatory","source":"Fierce Pharma","summary":"'Hub-and-spoke' biotech BridgeBio scores first FDA approval with Alexion castoff - Fierce Pharma","headline":"'Hub-and-spoke' biotech BridgeBio scores first FDA approval with Alexion castoff","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNVm8wVk5xSXFnVE1xSHFuLUhRVHpLaWNQNHd4LWVsY2NoY3QzNDF5RHFVSXJFQWlDWkZ6RHdqRk1JODlsLU5yMU56bl9hRTJRN3lUbUJBblRjSXVRcGp6ZlQ5RFdrOUNIV3h3U1lubjliOTkxU2NHMnpjTjAzR2ItV29qYWJhM0Q5U1AtY244Ujd6ajJKWXJROTJSeVVCTFQ4Z0d0am1FNHo?oc=5","date":"2021-03-01","type":"regulatory","source":"Medical Professionals Reference","summary":"Nulibry Approved for Molybdenum Cofactor Deficiency Type A - Medical Professionals Reference","headline":"Nulibry Approved for Molybdenum Cofactor Deficiency Type A","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPYVJSblZMYU9uOGFkaEVjSE1xOFNvMlZuVF9mNlNjOTRqUV9IaFBlVjFVSzkwbTlpbV83UDUzY09Sa3NuU2dxbDBvZnoxWFNxNGRNamRHYndMbkY1ZzJNcWczN1B1eVlPYThmMGtoYnc1Z0xYN2JUdDFFdFpEZEtWUzlJR3NKOEpXZGdiY25veVRjbnBBc0xXSVZDMkFESG5JQ3lFd1JHV0k?oc=5","date":"2021-02-26","type":"regulatory","source":"The Business Journals","summary":"Tackling deadly newborn disease, BridgeBio affiliate wins FDA drug approval - The Business Journals","headline":"Tackling deadly newborn disease, BridgeBio affiliate wins FDA drug approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxOTS1EakhJTlc1N29xRDBLZjlBZ2VpeWZJUGVaaFNzUmtnLXZRT3kwNGtiU0Y0ZGU3bm5ZcHo2SVRvUVpkQUwxWmRIaU03YTRHaFVKTnFyMWRhRldON0NRMGJnRWNFd01UYTY2RjJZak9ReGJhd3ZmdHRKSlVXUHoySXpLaXhCZUZfS3Q1UkpOWHQwMXpNS1lmS1FvdElNZkJWczVOM1hFTDlwSEpTVjZUNFVLV3VzckU3MUc1ODFxUmtXSm1DMHg1blpQYUt6dTBYallZS1JVZEFybi1GcHZLc2lqXzU2eWhXcEZnM3diYVVrOURjWVpXQ0hlQnRYVFBJSWhZakhhOHFQaTBxaGNZOTBwdzMybkMwMTF4WWZ3QW45XzdCTEo1c0VveEJvU19ScVpPcHRiazNfQ0JVWlVqQ1VNOEVXc3JlTkE?oc=5","date":"2018-06-11","type":"deal","source":"PR Newswire","summary":"BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy - PR Newswire","headline":"BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Orig","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}